Skip Navigation


Cardiovascular Research Advance Access first published online on May 28, 2008
This version [Corrected Proof] published online on June 4, 2008
Cardiovascular Research, doi:10.1093/cvr/cvn132
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
79/3/355    most recent
cvn132v2
cvn132v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in Cardiovasc Res
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Menasché, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Menasché, P.
Related Collections
Right arrowRelated Article
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2008. For permissions please email: journals.permissions@oxfordjournals.org

Towards the second generation of skeletal myoblasts?

Philippe Menasché

Assistance Publique-Hôpitaux de Paris, Hôpital Européen Georges Pompidou, Department of Cardiovascular Surgery; University Paris Descartes, Faculté de Médecine; INSERM U 633, Paris, France

Corresponding author. Tel: +33 1 56 09 29 62; fax: +33 1 56 09 22 19. E-mail address: philippe.menasche@hop.egp.ap-hop-paris.fr

This editorial refers to ‘CSF-1 transfection of myoblasts improves the repair of failing myocardium following autologous myoblast transplantation’ by Aharinejad et al., doi:10.1093/cvr/cvn097

The first 10% of the full text of this article appears below.

It is now widely accepted that the putative benefits of cell transplantation are hampered by the high rate of cell death that occurs shortly after the procedure. While this event may not be so relevant to bone-marrow-derived cellular grafts whose efficacy seems to depend on cell functionality rather than on the absolute numbers of delivered cells,1 such is not the case for skeletal myoblasts for which a dose-effect relationship has been demonstrated.2 It thus appears to be sound to speculate that outcomes of myoblast transplantation could be improved if cell survival was enhanced.

Although post-delivery cell death is a complex phenomenon which involves several intricate factors, three of them have been . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related articles in Cardiovasc Res:

Colony-stimulating factor-1 transfection of myoblasts improves the repair of failing myocardium following autologous myoblast transplantation
Seyedhossein Aharinejad, Dietmar Abraham, Patrick Paulus, Karin Zins, Michael Hofmann, Wolfgang Michlits, Mariann Gyöngyösi, Karin Macfelda, Trevor Lucas, Karola Trescher, Michael Grimm, and E. Richard Stanley
Cardiovasc Res 2008 79: 395-404. [Abstract] [FREE Full Text]  

Related Article

Colony-stimulating factor-1 transfection of myoblasts improves the repair of failing myocardium following autologous myoblast transplantation
Seyedhossein Aharinejad, Dietmar Abraham, Patrick Paulus, Karin Zins, Michael Hofmann, Wolfgang Michlits, Mariann Gyöngyösi, Karin Macfelda, Trevor Lucas, Karola Trescher, Michael Grimm, and E. Richard Stanley
Cardiovasc Res 2008 79: 395-404. [Abstract] [Full Text] [PDF]



This article has been cited by other articles:


Home page
 Mayo Clin Proc.Home page
B. J. Gersh, R. D. Simari, A. Behfar, C. M. Terzic, and A. Terzic
Cardiac Cell Repair Therapy: A Clinical Perspective
Mayo Clin. Proc., October 1, 2009; 84(10): 876 - 892.
[Abstract] [Full Text] [PDF]